SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1% ...
Medtronic (NYSE:MDT) today announced three-year results from the SMART trial comparing its Evolut heart valve to Edwards' ...
WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 7 years, there was no difference in clinical outcomes ...
Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results